Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. Issue 4 (August 2015) - Nguyen-Nielsen, Mary
Highlights We examined prognosis of patients with ADT-treated nonmetastatic prostate cancer. Among the 2494 patients, one-fourth developed metastases within 5 years. High PSA level and short PSA doubling time predicted mortality and bone metastasis.